NASDAQ:NK - NantKwest Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.00
  • Forecasted Upside: 3.57 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$17.38
▲ +0.12 (0.70%)
1 month | 3 months | 12 months
Get New NantKwest Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NK

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$18.00
▲ +3.57% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for NantKwest in the last 3 months. The average price target is $18.00, with a high forecast of $18.00 and a low forecast of $18.00. The average price target represents a 3.57% upside from the last price of $17.38.
Buy
The current consensus among 1 investment analysts is to buy stock in NantKwest. This rating has held steady since May 2020, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
1/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
4/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/8/2020Piper SandlerInitiated CoverageOverweight$18.00High
i
5/30/2019CitigroupDowngradeNeutral ➝ Sell$1.25 ➝ $1.00High
i
12/9/2018CitigroupLower Price TargetSell ➝ Neutral$3.00 ➝ $2.00Medium
i
Rating by Wendy Nicholson at Citigroup Inc.
12/2/2018CitigroupLower Price Target$3.00Low
i
Rating by Wendy Nicholson at Citigroup Inc.
11/30/2018CitigroupUpgradeSell ➝ Neutral$3.00 ➝ $2.00Medium
i
Rating by Wendy Nicholson at Citigroup Inc.
11/15/2018Jefferies Financial GroupReiterated RatingHold$3.50Low
i
10/16/2018CitigroupDowngradeNeutral ➝ SellHigh
i
Rating by Wendy Nicholson at Citigroup Inc.
8/10/2018CitigroupDowngradeHold$3.00Low
i
Rating by Wendy Nicholson at Citigroup Inc.
8/9/2018CitigroupUpgradeSell ➝ NeutralHigh
i
12/11/2017Raymond JamesReiterated RatingHoldMedium
i
Rating by Reni Benjamin at Raymond James
8/14/2017CitigroupSet Price TargetSell$3.00Low
i
5/15/2017CitigroupDowngradeNeutral ➝ Sell$3.00High
i
5/8/2017Jefferies Financial GroupSet Price TargetHold$4.00Medium
i
3/17/2017(FBRC)Reiterated RatingOutperform ➝ Outperform$22.00 ➝ $9.00Low
i
1/24/2017Jefferies Financial GroupDowngradeBuy ➝ Hold$6.00N/A
i
8/19/2016Canaccord GenuityReiterated RatingBuy$18.00N/A
i
8/17/2016Piper Jaffray CompaniesReiterated RatingOverweight$32.00 ➝ $23.00N/A
i
6/12/2016Canaccord GenuityReiterated RatingBuyN/A
i
6/2/2016Raymond JamesInitiated CoverageMarket PerformN/A
i
(Data available from 4/18/2016 forward)
NantKwest logo
NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $17.38
$16.15
$17.38

50 Day Range

MA: $28.01
$16.09
$38.70

52 Week Range

Now: $17.38
$2.52
$45.42

Volume

896,410 shs

Average Volume

1,568,129 shs

Market Capitalization

$1.90 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.61

Frequently Asked Questions

What sell-side analysts currently cover shares of NantKwest?

The following sell-side analysts have issued reports on NantKwest in the last year: Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for NK.

What is the current price target for NantKwest?

1 Wall Street analysts have set twelve-month price targets for NantKwest in the last year. Their average twelve-month price target is $18.00, suggesting a possible upside of 3.6%. Piper Sandler has the highest price target set, predicting NK will reach $18.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $18.00 for NantKwest in the next year.
View the latest price targets for NK.

What is the current consensus analyst rating for NantKwest?

NantKwest currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NK will outperform the market and that investors should add to their positions of NantKwest.
View the latest ratings for NK.

What other companies compete with NantKwest?

How do I contact NantKwest's investor relations team?

NantKwest's physical mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is 858-633-0300 and its investor relations email address is [email protected] The official website for NantKwest is www.nantkwest.com.